We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Exelixis’ Cabozantinib Fails in Prostate Cancer Trial

Exelixis’ Cabozantinib Fails in Prostate Cancer Trial

September 8, 2014

San Francisco-based drugmaker Exelixis is halting research into the use of its thyroid cancer therapy Cometriq for treating prostate cancer after the drug failed a Phase III trial for that indication.

Median overall survival rates were not statistically significant in men taking the drug for metastatic treatment-resistant prostate cancer, only 1.2 months longer than patients given prednisone, a generic drug that treats inflammation and some types of cancer, the company said Tuesday. Cometriq (cabozantinib) did slightly better with progression-free survival, extending the time to disease progression by 2.7 months longer than prednisone.

Progression-free survival, however, is not an endpoint that has resulted in approval for other prostate-cancer drugs, Chief Medical Officer Gisela Schwab told a Tuesday teleconference to discuss the results.

As a result of the study outcomes, the company said it will reduce its workforce by 160 people, leaving roughly 70 employees remaining.

Exelixis is still sorting through secondary and exploratory endpoint data from the trial, Schwab said. Enrollment in another Phase III trial evaluating cabozantinib for pain palliation also was halted. Results from this trial, which are expected later this year, will decide whether the company will continue to explore the drug for treating prostate cancer, she added.

Meanwhile, the company continues to study the drug for metastatic kidney cancer and advanced liver cancer indications. A Phase Ib kidney cancer trial showed that the tumor shrank in 19 out of 21 patients, while a Phase II liver cancer trial had 4.4 months of progression-free survival and 15.1 months of overall survival.

Cometriq won FDA approval in 2012 for progressive, metastatic medullary thyroid cancer, and European approval for progressive, unresectable locally advanced or metastatic MTC. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Research and Development

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing